The Evolving Role of Angiogenesis Inhibition in Treatment of Breast Cancer CME
Monday, November 13, 2006; 5:00 PM Eastern Presenters: Joseph Sparano, MD, and Kathy D. Miller, MD Disclosures
Release Date: November 13, 2006; Valid for credit through November 13, 2007
Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians
Contents of ThisCMEActivity
Archived Web Conference Introduction The Evolving Role of Angiogenesis Inhibition in Metastatic Breast Cancer Questions & Answers Antiangiogenesis As A Treatment Approach for Patients With Breast Cancer Questions & Answers
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Contact This Provider
